Mizoribine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Nephrotic syndrome; Rheumatoid arthritis 50 mg 3 times/day. As an immunosuppressant in renal transplant patients 1-3 mg/kg/day.
Dosage Details
Oral
Immunosuppressant in renal transplant patients
Adult: 1-3 mg/kg daily. Higher doses (>5 mg/kg daily) have been used.

Oral
Nephrotic syndrome, Rheumatoid arthritis
Adult: For nephrotic syndrome associated with primary glomerular disease or lupus nephritis: 50 mg tid.
Contraindications
Hypersensitivity.
Special Precautions
Doses must be reviewed regularly in renal transplant patients to ensure that plasma drug level is in the therapeutic range. Monitor serum uric acid regularly during treatment. Increased risk of infections and malignancy. Use with caution in patients with active disorders of the GI tract. Live vaccines should also be avoided.
Adverse Reactions
Hyperuricaemia. GI symptoms.
Drug Interactions
Increased risk of rhabdomyolysis when used concurrently with bezafibrate.
Action
Description: Mizoribine is an imidazole nucleoside originally isolated from Eupenicillium brefedianum. It is an immunosuppressant that works by blocking the purine biosynthesis pathway and inhibiting mitogen-stimulated T-and B-cell proliferation.
Pharmacokinetics:
Absorption: Rapidly absorbed from the intestines.
Excretion: Almost completely excreted within 24 hr; mainly in urine (85%) and in the bile (1%).
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Mizoribine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in